{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:24:07Z","timestamp":1740147847298,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11886-021-01472-9","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T10:04:31Z","timestamp":1615457071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevention and Management of Urgent\/Emergent Limb Ischemia"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1639-6359","authenticated-orcid":false,"given":"Graham R.","family":"McClure","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Kaplovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinai","family":"Bhagirath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"12","key":"1472_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350\u20137. https:\/\/doi.org\/10.1001\/jama.2010.1322.","journal-title":"JAMA."},{"issue":"2","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.295.2.180","volume":"295","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180\u20139. https:\/\/doi.org\/10.1001\/jama.295.2.180.","journal-title":"JAMA."},{"issue":"9","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco J-B, Bartelink M-LEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763\u2013816. https:\/\/doi.org\/10.1093\/eurheartj\/ehx095.","journal-title":"Eur Heart J"},{"issue":"16","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jacc.2016.02.040","volume":"67","author":"S Agarwal","year":"2016","unstructured":"Agarwal S, Sud K, Shishehbor MH. Nationwide trends of hospital admission and outcomes among critical limb ischemia patients: from 2003 to 2011. J Am Coll Cardiol. 2016;67(16):1901\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.040.","journal-title":"J Am Coll Cardiol"},{"key":"1472_CR5","doi-asserted-by":"crossref","unstructured":"\u2022 Kaplovitch E, Eikelboom JW, Dyal L, et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol. Published online September 30, 2020. 10.1001\/jamacardio.2020.4390. Findings from this study demonstrate that risk of MACE and MALE in PAD patients is significantly elevated in those with prior amputation, Fontaine III or IV symptoms, and those with previous lower extremity revascularization as well as those with high-risk metabolic comorbidities.","DOI":"10.1001\/jamacardio.2020.4390"},{"issue":"2","key":"1472_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000697","volume":"3","author":"EJ Armstrong","year":"2014","unstructured":"Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697. https:\/\/doi.org\/10.1161\/JAHA.113.000697.","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","volume":"71","author":"SS Anand","year":"2018","unstructured":"Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018;71(20):2306\u201315. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.008 Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease.","journal-title":"J Am Coll Cardiol"},{"key":"1472_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"219","author":"SS Anand","year":"2017","unstructured":"Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2017;219:229. https:\/\/doi.org\/10.1016\/S0140-6736(17)32409-1.","journal-title":"Lancet Lond Engl"},{"issue":"41","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","volume":"35","author":"DJ Kumbhani","year":"2014","unstructured":"Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Goto S, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehu080.","journal-title":"Eur Heart J"},{"issue":"2","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1016\/j.atherosclerosis.2008.10.023","volume":"204","author":"PP Cacoub","year":"2009","unstructured":"Cacoub PP, Abola MTB, Baumgartner I, Bhatt DL, Creager MA, Liau CS, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009;204(2):e86\u201392. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.10.023.","journal-title":"Atherosclerosis."},{"key":"1472_CR11","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1056\/NEJMoa2000052","volume":"0","author":"MP Bonaca","year":"2020","unstructured":"\u2022\u2022 Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;0:0. https:\/\/doi.org\/10.1056\/NEJMoa2000052. Findings from this study demonstrate that aspirin and rivaroxaban 2.5 mg twice daily significantly reduce major cardiac and limb events following peripheral revascularization.","journal-title":"N Engl J Med"},{"key":"1472_CR12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJMoa1709118","volume":"1319","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;1319:1330. https:\/\/doi.org\/10.1056\/NEJMoa1709118.","journal-title":"N Engl J Med"},{"issue":"2","key":"1472_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1358863X18820123","volume":"24","author":"E Kaplovitch","year":"2019","unstructured":"Kaplovitch E, Rannelli L, Anand SS. Antithrombotics in stable peripheral artery disease. Vasc Med Lond Engl. 2019;24(2):132\u201340. https:\/\/doi.org\/10.1177\/1358863X18820123.","journal-title":"Vasc Med Lond Engl"},{"issue":"2","key":"1472_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7326\/M17-1058","volume":"168","author":"EA Secemsky","year":"2018","unstructured":"Secemsky EA, Schermerhorn M, Carroll BJ, Kennedy KF, Shen C, Valsdottir LR, et al. Readmissions after revascularization procedures for peripheral arterial disease: a nationwide cohort study. Ann Intern Med. 2018;168(2):93\u20139. https:\/\/doi.org\/10.7326\/M17-1058.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1472_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/CIRCULATIONAHA.117.027625","volume":"136","author":"D Kolte","year":"2017","unstructured":"Kolte D, Kennedy KF, Shishehbor MH, Abbott JD, Khera S, Soukas P, et al. Thirty-day readmissions after endovascular or surgical therapy for critical limb ischemia: analysis of the 2013 to 2014 Nationwide Readmissions Databases. Circulation. 2017;136(2):167\u201376. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.027625.","journal-title":"Circulation."},{"issue":"3","key":"1472_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jvs.2014.03.244","volume":"60","author":"DT Baril","year":"2014","unstructured":"Baril DT, Ghosh K, Rosen AB. Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population. J Vasc Surg. 2014;60(3):669\u2013677.e2. https:\/\/doi.org\/10.1016\/j.jvs.2014.03.244.","journal-title":"J Vasc Surg"},{"issue":"1","key":"1472_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","volume":"376","author":"WR Hiatt","year":"2017","unstructured":"Hiatt WR, Fowkes FGR, Heizer G, Berger JS, Baumgartner I, Held P, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376(1):32\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1611688.","journal-title":"N Engl J Med"},{"issue":"7","key":"1472_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/CIRCULATIONAHA.119.039773","volume":"140","author":"CN Hess","year":"2019","unstructured":"Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, et al. Acute limb ischemia in peripheral artery disease. Circulation. 2019;140(7):556\u201365. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.039773.","journal-title":"Circulation."},{"issue":"8","key":"1472_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/jamasurg.2016.0415","volume":"151","author":"MA Hussain","year":"2016","unstructured":"Hussain MA, Al-Omran M, Mamdani M, et al. Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease. JAMA Surg. 2016;151(8):742\u201350. https:\/\/doi.org\/10.1001\/jamasurg.2016.0415.","journal-title":"JAMA Surg"},{"issue":"1","key":"1472_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/CIRCULATIONAHA.110.003954","volume":"124","author":"RL Pande","year":"2011","unstructured":"Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124(1):17\u201323. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.003954.","journal-title":"Circulation."},{"issue":"13","key":"1472_CR21","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIR.0b013e31828b82aa","volume":"127","author":"JL Anderson","year":"2013","unstructured":"Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF\/AHA guideline recommendations): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(13):1425\u201343. https:\/\/doi.org\/10.1161\/CIR.0b013e31828b82aa.","journal-title":"Circulation."},{"issue":"12","key":"1472_CR22","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1161\/CIR.0000000000000470","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC Guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12):e686\u2013725. https:\/\/doi.org\/10.1161\/CIR.0000000000000470.","journal-title":"Circulation."},{"issue":"16","key":"1472_CR23","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jacc.2007.11.077","volume":"51","author":"GMJM Welten","year":"2008","unstructured":"Welten GMJM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51(16):1588\u201396. https:\/\/doi.org\/10.1016\/j.jacc.2007.11.077.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1472_CR24","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","volume":"69","author":"JS Berger","year":"2017","unstructured":"Berger JS, Ladapo JA. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. J Am Coll Cardiol. 2017;69(18):2293\u2013300. https:\/\/doi.org\/10.1016\/j.jacc.2017.02.064.","journal-title":"J Am Coll Cardiol"},{"key":"1472_CR25","unstructured":"AN Sidawy BP. Rutherford\u2019s Vascular Surgery and Endovascular Therapy, 9th Edition. 9th ed."},{"issue":"2","key":"1472_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejvs.2019.09.006","volume":"59","author":"M Bj\u00f6rck","year":"2020","unstructured":"Bj\u00f6rck M, Earnshaw JJ, Acosta S, Bastos Gon\u00e7alves F, Cochennec F, Debus ES, et al. Editor\u2019s Choice \u2013 European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the management of acute limb ischaemia. Eur J Vasc Endovasc Surg. 2020;59(2):173\u2013218. https:\/\/doi.org\/10.1016\/j.ejvs.2019.09.006.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"10","key":"1472_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.115.019355","volume":"133","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2\u00b0P-TIMI 50). Circulation. 2016;133(10):997\u20131005. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.019355.","journal-title":"Circulation."},{"key":"1472_CR28","doi-asserted-by":"publisher","unstructured":"McClure GR, Kaplovitch E, Chan N, et al. A national canadian survey of antithrombotic therapy following urgent and emergent limb revascularization. Can J Cardiol. 2020. https:\/\/doi.org\/10.1016\/j.cjca.2020.06.008.","DOI":"10.1016\/j.cjca.2020.06.008"},{"issue":"1","key":"1472_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2005.03.021","volume":"151","author":"WAVE Investigators","year":"2006","unstructured":"Investigators WAVE. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J. 2006;151(1):1\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2005.03.021.","journal-title":"Am Heart J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01472-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-021-01472-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01472-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T11:20:41Z","timestamp":1620645641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-021-01472-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1007\/s11886-021-01472-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"type":"print","value":"1523-3782"},{"type":"electronic","value":"1534-3170"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"11 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Vinai Bhagirath reports grants from Pfizer, Canada, and personal fees from Bayer. Sonia S. Anand reports consulting fees from Bayer and Janssen. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"41"}}